Anidulafungin

Generic Name: Anidulafungin

Brand Names: Ecalta, Eraxis

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₇₃N_₇O_₁₇

CAS Number: 166663-25-8

Unique Ingredient Identifier: 9HLM53094I

Background: Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.

Indication: 用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。

Associated Conditions: Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis

Associated Therapies: -

Clinical Trials

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Phase 3

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin
Drug: Fluconazole

First Posted Date: 2008-09-29

Last Posted Date: 2019-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 70

Registration Number: NCT00761267

Locations: 🇧🇷
Hospital Pequeno Principe, Curitiba, PR, Brazil
🇰🇷
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
🇺🇸
University of California - Los Angeles - Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 41 locations

Anidulafungin PK in Infants and Toddlers

Phase 1

Completed

Conditions: Invasive Fungal Infections

Interventions: Drug: Anidulafungin

First Posted Date: 2008-08-14

Last Posted Date: 2012-11-21

Lead Sponsor: Michael Cohen-Wolkowiez

Target Recruit Count: 15

Registration Number: NCT00734500

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

Phase 3

Completed

Conditions: Invasive Candidiasis

Interventions: Drug: Anidulafungin
Drug: Fluconazole
Drug: Voriconazole

First Posted Date: 2008-06-03

Last Posted Date: 2011-05-30

Lead Sponsor: Pfizer

Target Recruit Count: 216

Registration Number: NCT00689338

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Phase 4

Terminated

Conditions: Aspergillosis

Interventions: Drug: voriconazole
Drug: anidulafungin

First Posted Date: 2008-02-21

Last Posted Date: 2010-02-15

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00620074

Locations: 🇺🇸
Pfizer Investigational Site, Fort Worth, Texas, United States

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Phase 4

Completed

Conditions: Candidemia
Invasive Candidiasis

Interventions: Drug: Anidulafungin
Drug: Voriconazole

First Posted Date: 2007-10-23

Last Posted Date: 2011-01-17

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT00548262

Locations: 🇵🇦
Pfizer Investigational Site, Panama, Panama

Anidulafungin In Treatment Of Candidemia In Asian Subjects

Phase 3

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2007-10-01

Last Posted Date: 2010-03-09

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00537329

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Phase 3

Completed

Conditions: Aspergillosis

Interventions: Drug: voriconazole
Drug: anidulafungin

First Posted Date: 2007-09-18

Last Posted Date: 2012-04-30

Lead Sponsor: Pfizer

Target Recruit Count: 459

Registration Number: NCT00531479

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Antimicrobial PK in Infants With Suspected or Confirmed Infection

Completed

Conditions: Infection

Interventions: Drug: Ampicillin
Drug: Metronidazole
Drug: Piperacillin/Tazobactam
Drug: Acyclovir
Drug: Amphotericin B
Drug: Ambisome
Drug: Anidulafungin
Drug: Caspofungin

First Posted Date: 2007-06-26

Last Posted Date: 2012-11-19

Lead Sponsor: Duke University

Target Recruit Count: 450

Registration Number: NCT00491426

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of California at San Diego, La Jolla, California, United States

and more 3 locations

Anidulafungin in Treating Immunocompromised Children With Neutropenia

Phase 1

Completed

Conditions: Infection
Neutropenia
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-09-11

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00068471

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

and more 2 locations

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

Phase 3

Completed

Conditions: Candida
Candidiasis

First Posted Date: 2003-04-11

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 248

Registration Number: NCT00058682

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy